Egyptian Drug Authority (EDA) signed a Memorandum of Understanding (MoU) on Thursday with the Brazilian Health Regulatory Agency (ANVISA) to enhance technical and regulatory collaboration in the pharmaceutical sector. The agreement is aimed to support the availability of safe and effective medicines and establish a foundation for future scientific and research cooperation between the two countries. According to the cabinet statement, the partnership with ANVISA reflects growing international confidence in the strength and efficiency of Egypt's pharmaceutical system and its leadership at both the regional and global levels. The agreement supports Egypt's strategy to broaden its international presence and benefit from global expertise in regulatory development, helping to ensure the quality, safety, and efficacy of medical products in the local market. It also aligns with ongoing efforts to foster innovation and attract investment in the pharmaceutical sector. Officials from the Brazilian agency described the MoU as a strategic step towards deeper cooperation between the two regulatory systems. The agreement is expected to facilitate the exchange of technical and scientific knowledge, while promoting joint initiatives in pharmaceutical research, training, and inspection. Moreover, the collaboration aims to strengthen integration between Egypt and Brazil and enhance regulatory system performance to better protect public health in both countries. Attribution: Amwal Al Ghad English Subediting: M. S. Salama
